Business Context and Reporting Period
Company: SANUWAVE Health, Inc. (SNWV)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2025
Business Overview: The Company commercializes patented regenerative medicine utilizing noninvasive ultrasound and shockwaves (UltraMIST® and PACE®) for tissue repair. As of November 3, 2025, there were 8,576,164 shares of common stock outstanding. The Company is classified as a smaller reporting company.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2025 | Nine Months Ended Sept 30, 2025 |
|---|---|---|
| Revenue | $11.45 million | $30.96 million |
| Gross Margin | $8.93 million (78%) | $24.27 million (78%) |
| Operating Income | $1.47 million | $4.33 million |
| Net Income | $10.33 million | $5.70 million |
| Cash and Equivalents | $9.60 million (as of Sept 30, 2025) | |
| Total Debt (Principal) | $23.66 million ($23.0M Term Loan + $0.66M Revolver) | |
| Working Capital | $3.06 million (Current Assets $22.6M - Current Liabilities $19.6M) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 22% year-over-year (YoY) for the quarter and 39% YoY for the nine-month period, driven by a 23% increase in UltraMIST® disposable sales volume and a 25% increase in system sales volume for the quarter.
- Profitability Turnaround: The Company reported Net Income of $10.33 million for the quarter, a significant improvement from a Net Loss of $20.66 million in the same period in 2024. This shift was primarily driven by non-operating items (see below).
- Debt Refinancing: In September 2025, the Company refinanced its senior secured debt, replacing the previous facility with a new $23.0 million secured term loan and a $5.0 million secured revolving credit facility from JPMorgan Chase. This action alleviated substantial doubt regarding the Company's ability to continue as a going concern.
- Expense Increases: General and Administrative (G&A) expenses rose 89% YoY for the quarter, largely due to $1.4 million in stock-based compensation and increased headcount.
Outlook, Risks, and Unusual Items
Unusual Items and Non-GAAP Adjustments
- Patent Sale Gain: The Company recognized a one-time gain of $5.0 million from the sale of a patent portfolio to a third-party licensee in August 2025, recorded as "Other Income."
- Derivative Liability Changes: A $6.1 million gain resulted from the change in fair value of warrant liabilities for the quarter, compared to an $18.8 million loss in the prior year quarter.
- Adjusted EBITDA: For the nine months ended September 30, 2025, Adjusted EBITDA was $9.17 million, compared to $3.51 million in the prior year period.
Risks and Contingencies
- Internal Controls: The Company disclosed that its disclosure controls and procedures were not effective as of September 30, 2025. Material weaknesses persist in key accounting and IT processes, including equity, financial reporting, and complex financial instruments. Management is implementing a remediation plan involving new software and personnel.
- Supplier Concentration: The Company relies on single suppliers for most product component materials; loss of these suppliers could disrupt production.
- Tax Attributes: An IRC Section 382 analysis indicated that $44.2 million of Net Operating Loss (NOL) tax attributes will expire before becoming available due to ownership shifts.
Investor Verification Checklist
- Debt Covenants: Verify compliance with the new JPM Credit Agreement covenants, specifically financial ratios and restrictions on additional indebtedness.
- Internal Control Remediation: Monitor the progress of the remediation plan for material weaknesses in internal controls over financial reporting to assess future reporting reliability.
- Recurring Revenue Quality: Distinguish between recurring operating income and one-time gains (patent sale, derivative valuation changes) to assess sustainable profitability.
- Supplier Dependencies: Review supply chain contracts given the high concentration of purchases from single vendors (Vendor A accounted for 31% of purchases in Q3).
- Stock-Based Compensation: Evaluate the impact of the 2024 Equity Incentive Plan and performance-based awards on future expense structures.